Safety of ciprofloxacin in neonates with sepsis

Maurizio Bonati, Chiara Pandolfini, Florentia Kaguelidou, Evelyne Jacqz-Aigrain, Mark Turner, Imti Choonara

Research output: Contribution to journalArticle

Abstract

Newborn sepsis is a major cause of child mortality across the world. Strategies for prevention and treatment have the potential to save many newborns from a sepsis-related death. Among the various parenteral antibiotic options possible, there is considerable experience with the use of penicillins, cephalosporins, and aminoglycosides. Ciprofloxacin is also increasingly accepted as safe in the neonate. However, the available evidence is not of high quality, and adequate research is required to specifically address dosage schedules, safety, and efficacy of ciprofloxacin to lead to established interventions to reduce morbidity and mortality for neonatal sepsis.

Original languageEnglish
Pages (from-to)1019-1022
Number of pages4
JournalAdverse Drug Reaction Bulletin
Issue number265
DOIs
Publication statusPublished - Dec 2010

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Safety of ciprofloxacin in neonates with sepsis'. Together they form a unique fingerprint.

Cite this